Case-Based Roundtable
General Dermatology
Eczema
Chronic Hand Eczema
Chronic Spontaneous Urticaria
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management
Prurigo Nodularis
Buy-and-Bill

Article

December 8, 2008

LEO Pharma establishes company in China

Shanghai, China - LEO Pharma is establishing a strategic company in China to market drugs for the treatment of psoriasis and other skin diseases, MarketWatch reports.

Shanghai, China

- LEO Pharma is establishing a strategic company in China to market drugs for the treatment of psoriasis and other skin diseases, MarketWatch reports.

LEO Pharma China, the new company, will market Daivobet, LEO Pharma's psoriasis brand, which was recently approved by the Chinese authorities in order to market the drug in China.

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe Now!